Biofarma Group, the global CDMO partner in health & beauty care

The corporate headquarters are located in Italy, but with more than 1,500 employees and 8 manufacturing sites geographically crossing the continents of Europe, America and Asia, Biofarma ensures a truly global offering. Each plant boasts cutting-edge technological production skills and operates synergistically to meet the customers’ requirements.

As the only global Health & Beauty Care CDMO, the Group guides companies from concept to market, offering a seamless pathway to success by fusing extensive capabilities with a thorough understanding of Health and Beauty Care trends.

Being a preferred outsourcing partner means being ready to support the challenges customers face today and tomorrow:

Biofarma Group operates day-to-day according to an approach that places humans and their needs at the centre, in order to promote a progress that prioritises the well-being of humans, the environment and sustainability, for the benefit of the entire community.

In order to do this, the Group develops safe and effective products targeting different fields of human health and offering a wide range of dosage forms and packaging services, meeting the highest standard of quality and reliability together with advanced manufacturing capabilities.

The technologies range from solids (tablets, film-coated tabs, chewable, beadlets, multi-layer, ODT’s, effervescent tabs) and semi-solids (emulsions, gels, creams and pastes, butters, scrubs and muds) to powders (microencapsulated powders, granules, orosolube powders, water-dispersible powders) and liquids (liquids, oils, multi-phasic).

In the probiotic field, in particular, Biofarma Group develops probiotic-based solutions released as nutritional supplements and drugs, and enriched with galenic forms including capsules, tablets, powders and the innovative nutritional supplement Oildrop. The Group boats two dedicated and independent manufacturing sites in Italy and in the US, designed to be ISO-8 clean spaces with strict temp, humidity and airflow standards.

The Group's production excellence in the probiotic field allows customers to stay abreast with a growing global trend. According to data, in fact, the global probiotic market is expected to be worth $75.9 billion by 2027 (the market size was estimated at $54.21 billion in 2020). The dietary supplement market is evolving towards an increased focus on microbiome health with consumers becoming increasingly open to using probiotics for managing their wellbeing beyond digestive health. Examples of new health indications for probiotics include skin health, metabolic health, bone health, mood/stress, and migraine headaches. The Group’s R&D labs are increasingly working on very specific therapeutic and generational target solutions to offer customised and scientifically solid products.

To achieve this goal, research in Biofarma Group can count on two distinct divisions of professionals of the highest technical and scientific level: RESEARCH & INNOVATION CENTRE and DEVELOPMENT CENTRE.

R&I is a team of professionals who every day are sparks and constant stimulus for development and improvement, oriented towards a unique and differentiating future: a permanent look at the future, with the awareness that we no longer must solely rely upon internal ideas and resources but can also explore external solutions, knowledge and technological expertise, thanks to an ecosystem of innovators made up of start-ups, universities, research institutes and suppliers.

The Development team is staffed by over 50 specialists with strong multi-sector technical skills ranging from nutraceuticals, to cosmetics, medical devices and probiotics. Flexibility, open-mindedness and the ability to adapt to any type of request are the pillars and cornerstones of the team's work, which starts with an idea, continues with galenic development, and is completed with its industrialisation.

Biofarma Group develops over 2,000 annual projects, many of which become products with a high content of innovation capable of establishing themselves on the market as leading products for their quality, sometimes accompanied by clinical studies that testify to the effectiveness of the formulations.

Staying power, consistency, competition, and a creative spirit have allowed Biofarma Group to write a success story in becoming not only a great group, but also a reliable partner in the international CDMO market.